Show simple item record

dc.contributor.authorParrish, A.
dc.contributor.authorGray, A.
dc.contributor.authorKredo, T.
dc.contributor.authorMaartens, G. 
dc.contributor.authorReubenson, G.
dc.contributor.authorCohen, K. 
dc.contributor.authorDe Waal, R.
dc.contributor.authorBlockman, M.
dc.contributor.authorNel, J.
dc.contributor.authorRees, H.
dc.date.accessioned2020-07-20T09:08:06Z
dc.date.available2020-07-20T09:08:06Z
dc.date.issued2020-04-22
dc.identifier.urihttps://infospace.mrc.ac.za/handle/11288/595269
dc.language.isoenen_US
dc.publisherSouth African National Department of Healthen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.titleLopinavir–ritonavir (LPV/r) for treatment of COVID‐19: evidence review of clinical benefits and harmsen_US
dc.typeOtheren_US
dc.contributor.departmentTamara Kredo: Cochrane South Africa, South African Medical Research Council)en_US
dc.research.unitSouth African Cochrane Centreen_US
dc.date.epub2020-04-22


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States